Search results
Showing 3001 to 3050 of 4091 results for patient
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]
Awaiting development Reference number: GID-TA11300 Expected publication date: TBC
Abatacept for treating active idiopathic inflammatory myopathies [TSID10095]
Awaiting development Reference number: GID-TA10993 Expected publication date: TBC
Awaiting development Reference number: GID-TA11490 Expected publication date: TBC
In development Reference number: GID-TA11425 Expected publication date: TBC
Awaiting development Reference number: GID-TA11494 Expected publication date: TBC
Awaiting development Reference number: GID-TA11326 Expected publication date: TBC
Awaiting development Reference number: GID-TA11469 Expected publication date: TBC
Awaiting development Reference number: GID-TA11840 Expected publication date: TBC
Surgical insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock
In development Reference number: GID-IPG10461 Expected publication date: 25 March 2026
Awaiting development Reference number: GID-TA11137 Expected publication date: TBC
Lipid disorders: FH assessment and diagnosis (historical readings) (IND260)
This indicator covers the percentage of patients with a total cholesterol reading greater than 7.5 mmol/litre when aged 29 years or under, or greater than 9.0 mmol/litre when aged 30 years or over, who have been: diagnosed with secondary hyperlipidaemia, or clinically assessed for familial hypercholesterolaemia, or referred for assessment for familial hypercholesterolaemia, or genetically diagnosed with familial hypercholesterolaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM244
Research to access pathway for investigational drugs for COVID-19 (RAPID C-19)
RAPID C-19’s role in reviewing potential COVID-19 treatments has now ended because we have moved back to routine commissioning arrangements for these treatments.
This guideline covers oral health, including dental health and daily mouth care, for adults in care homes. The aim is to maintain and improve their oral health and ensure timely access to dental treatment.
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]
In development Reference number: GID-TA10966 Expected publication date: TBC
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]
Awaiting development Reference number: GID-TA11360 Expected publication date: TBC
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]
Awaiting development Reference number: GID-TA11284 Expected publication date: TBC
Awaiting development Reference number: GID-TA11863 Expected publication date: TBC
In development Reference number: GID-TA10960 Expected publication date: TBC
Awaiting development Reference number: GID-TA11673 Expected publication date: TBC
In development Reference number: GID-TA11085 Expected publication date: TBC
In development Reference number: GID-TA11862 Expected publication date: TBC
Awaiting development Reference number: GID-TA11828 Expected publication date: TBC
Adalimumab for treating early Dupuytren's contracture [ID6276]
Awaiting development Reference number: GID-TA11363 Expected publication date: TBC
Awaiting development Reference number: GID-TA11835 Expected publication date: TBC
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]
Awaiting development Reference number: GID-TA11198 Expected publication date: TBC
In development Reference number: GID-TA11718 Expected publication date: TBC
Evidence-based recommendations on percutaneous venoplasty for chronic cerebrospinal venous insufficiency in people with multiple sclerosis. This involves inserting an inflatable balloon into veins in the neck and chest in an attempt to widen them.
View recommendations for HTG501Show all sections
Bipolar, schizophrenia and other psychoses: cervical screening (IND85)
This indicator covers the percentage of women aged 25 or over and who have not attained the age of 65 with schizophrenia, bipolar affective disorder and other psychoses whose notes record that a cervical screening test has been performed in the preceding 5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM20
This indicator covers the contractor establishing and maintaining a register of patients with atrial fibrillation, including patients with ‘AF resolved’. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM164
In development Reference number: GID-TA10998 Expected publication date: TBC
Awaiting development Reference number: GID-TA11626 Expected publication date: TBC
In development Reference number: GID-TA11615 Expected publication date: TBC
Awaiting development Reference number: GID-IPG10418 Expected publication date: TBC
In development Reference number: GID-TA11583 Expected publication date: TBC
In development Reference number: GID-TA11836 Expected publication date: TBC
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433]
Awaiting development Reference number: GID-TA11489 Expected publication date: TBC
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]
In development Reference number: GID-TA11699 Expected publication date: TBC
In development Reference number: GID-TA11658 Expected publication date: TBC
In development Reference number: GID-TA11801 Expected publication date: TBC
In development Reference number: GID-TA11866 Expected publication date: TBC
Awaiting development Reference number: GID-TA11811 Expected publication date: TBC
Awaiting development Reference number: GID-TA11868 Expected publication date: TBC
Awaiting development Reference number: GID-TA11375 Expected publication date: TBC
In development Reference number: GID-IPG10318 Expected publication date: 25 March 2026
Percutaneous insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock
In development Reference number: GID-IPG10404 Expected publication date: 25 March 2026
In development Reference number: GID-TA11695 Expected publication date: TBC
In development Reference number: GID-TA11716 Expected publication date: TBC
Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]
In development Reference number: GID-TA11818 Expected publication date: TBC
In development Reference number: GID-TA11765 Expected publication date: TBC
Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]
In development Reference number: GID-TA11859 Expected publication date: TBC